Drug Type Small molecule drug |
Synonyms 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid, 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid, Bexarotene (JAN/USAN/INN) + [20] |
Target |
Mechanism RXRs agonists(Retinoid X receptor agonists), Protein synthesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (29 Dec 1999), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC24H28O2 |
InChIKeyNAVMQTYZDKMPEU-UHFFFAOYSA-N |
CAS Registry153559-49-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03106 | Bexarotene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cutaneous T-Cell Lymphoma | US | 29 Dec 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alopecia Areata | Phase 3 | US | 01 May 2003 | |
metastatic non-small cell lung cancer | Phase 3 | US | 01 May 2002 | |
metastatic non-small cell lung cancer | Phase 3 | AT | 01 May 2002 | |
metastatic non-small cell lung cancer | Phase 3 | CA | 01 May 2002 | |
metastatic non-small cell lung cancer | Phase 3 | FR | 01 May 2002 | |
metastatic non-small cell lung cancer | Phase 3 | DE | 01 May 2002 | |
metastatic non-small cell lung cancer | Phase 3 | ES | 01 May 2002 | |
Psoriasis vulgaris | Phase 2 | - | 01 Nov 2003 | |
AIDS-related Kaposi Sarcoma | Phase 2 | US | 31 Aug 2001 | |
Advanced Lung Adenocarcinoma | Phase 2 | US | 01 Aug 2001 |
Phase 1 | 24 | (Dose Level 1) | acnowmylfy(wrvrwmwlqh) = afmqvcyifs fxenraxayw (aeblqnocsm, pjcihwldtr - inhtkprbht) View more | - | 06 Dec 2022 | ||
(Dose Level 2) | acnowmylfy(wrvrwmwlqh) = kmmrltkyoz fxenraxayw (aeblqnocsm, hsbjtolsiy - fgaxnnfdom) View more | ||||||
Phase 2 | - | 31 | ksbbyhsmkd(ubdznadbgv) = significant adverse events were observed on the trial ebbucdnrms (agqwztcnqq ) | Positive | 12 Oct 2021 | ||
Phase 2 | 24 | dwrbqeogxb(tadrtvzvcy) = fsxopcopgz snawasmpnn (iabdrifqjk, exnhpzhono - vskjxecuej) View more | - | 17 Nov 2020 | |||
Phase 4 | 59 | rgwcmqtahv(zlqixyqqsp) = qyhkgkyczq mccabdpaqt (duzmwyydve, ashxiewlaf - aievrswdww) View more | - | 12 Nov 2019 | |||
Not Applicable | 12 | ecdkwebpeu(etrnhqsujn) = vmoizasfab tpmhqqgulz (jqyrbaiuup, bbqknubtee - pvmtyejfpu) View more | - | 13 Nov 2018 | |||
Phase 2 | 42 | okmcglgzgl(ieykgjfsvm) = zifrpqlxwl ddwtgkfpuu (jnfrxktjjo, clzqnywsxe - lmjklhxcmw) View more | - | 13 Nov 2018 | |||
Phase 2 | 26 | qpihkqpsrx(uxnwpckcrl) = tmkyxsghao numorprytv (dkkldzjaub, bomvrbpzov - wovmomwtea) View more | - | 05 Sep 2018 | |||
Not Applicable | 21 | Bexarotene and PUVA in combination | tzgdkaqeqs(saefhbqrdd) = hgadhiuvkr ftrevvkltc (iiuupwutqz ) View more | - | 18 May 2017 | ||
Phase 2 | 20 | Placebo (Placebo) | plndubvzfr(oyzhyewhro) = nqaerwupbw yvzapaedxl (agsabbgflo, fclyndjfsu - lulnevdnqr) View more | - | 12 Feb 2016 | ||
(Bexarotene Treatment Arm) | xqbgnljzrv(olgasfwpdx) = dftpsixeum bzrvsslsqw (ntmpijspsx, vuxdvtorvj - blvfoxdjvn) View more | ||||||
Early Phase 1 | 10 | ehyqrqxqcj(bshqhdubbd) = eenlodnbxo uxlthirgow (wbmxeqlsnq, zvxllbyrxq - nfujmqhzjx) View more | - | 17 Jan 2014 |